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Although the acquisition of melanoma does not seem to be influ-
enced by female sex hormones (Gefeller et al, 1998), the outcome
of established melanoma does appear to be influenced by
endocrine status. Female patients with malignant melanoma have
some survival advantage as has become evident from recent multi-
variate analysis of large databases (reviewed in Miller and Mac
Neil, 1997). Some investigators have suggested a survival advan-
tage in pre- as opposed to post-menopausal women (Shaw et al,
1980; Karjalainen et al, 1988; Cocconi et al, 1992) but in another
large multi-variate analysis (Stidham et al, 1994) the female
advantage was equally strong in pre- and post-menopausal groups.
If female steroids confer some advantage in established
melanoma then one might expect this to be most evident in
pregnancy. However, the literature concerning melanoma progres-
sion in pregnancy presents a complex picture (MacKie et al,
1991). Pregnancy is often associated with hyperpigmentation of
the skin, clearly indicating an influence of steroids on melanocyte
biology. There are reports of melanoma progression being exacer-
bated by pregnancy (Slinguff and Seigler, 1992); paradoxically
there are also reports of reduced risk associated with early
childbearing and multi-parity (Shaw et al, 1978). One point on
which studies of melanoma in pregnancy do agree is that preg-
nancy-associated melanomas are often significantly thicker
than that of non-pregnancy-associated tumours. Intriguingly
these thicker tumours are not necessarily associated with a less
favourable prognosis than tumours arising in a non-pregnant
woman (Travers et al, 1995).
In animal studies, there are a small number of reports indicating
a female survival benefit with metastatic melanoma. In one study
using severe combined immunodeficient (SCID) mice, melanoma
cells produced liver metastases preferentially in male compared
with female mice (Ladanyi et al, 1995). A study using athymic
mice showed that oestrogen receptor-positive human melanomas
grew more slowly in females than in male mice (Feucht et al,
1988) and, intriguingly, dihydrotestosterone has been reported to
stimulate melanoma cell proliferation (Morvillo et al, 1995). In
the latter study increased survival of male nude mice transplanted
with melanoma tumours was seen when mice were given the
anti-androgen hydroxyflutamide.
The mechanism of the apparent female survival benefit in
melanoma has not been investigated in any great depth as yet nor
have its implications been exploited with respect to prevention
of initial metastasis. The depth of extension of malignant
melanocytes into the dermis is a key factor in prognosis of malig-
nant melanoma (Breslow et al, 1970). At present, patients
presenting with thin tumours undergo surgical excision but are not
usually offered any prophylactic treatment. With this objective in
mind, we recently examined patients’ sex steroid status and
disease progression and identified a significant decrease in sex
hormone binding globulin with disease progress in male but not
female patients (Miller et al, 1997). However, this particular study
had relatively few patients with advanced metastatic disease. In
vitro we found clear anti-invasive effects of 17b-oestradiol when
we examined invasion of a cutaneous melanoma cell line through
fibronectin (Dewhurst et al, 1997), despite the fact that the
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Summary Epidemiological studies show female survival benefit in advanced metastatic melanoma. In investigating a possible mechanism for
this female survival benefit, we have previously reported that the female steroid 17b-oestradiol significantly reduces invasion of a human
melanoma cell line (A375-SM cells) and ocular melanoma cells through fibronectin. Neither cell type was found to possess oestrogen
receptor-a. The aim of the current study was to obtain further information on the extent to which progression of cutaneous melanoma might
be sex steroid sensitive by (a) examining the relationship between circulating sex steroids, sex hormone binding globulin and disease
progression; (b) examining the relationship between sex steroid structure and the ability of steroids to reduce invasion of a melanoma cell line
in vitro; and (c) examining the effects of sex steroids on proliferation of these cells in vitro. We report a significant reduction in circulating
oestrone with disease progression in male but not female patients. Examining steroids for their ability to inhibit invasion of A375-SM cells
through fibronectin in vitro, oestrogenic compounds (17b-oestradiol and oestrone) were found to inhibit invasion; in this respect, oestrone was
approximately 50 times more potent than 17b-oestradiol; steroids lacking the benzene ring structure did not inhibit invasion, indeed
dehydroepiandrosterone (DHEA) which acts as a precursor to androgenic steroids significantly enhanced invasion. Proliferation of A375-SM
cells was unaffected by 17b-oestradiol, oestrone or dihydrotestosterone when cells were cultured on plastic; in contrast, all three steroids
induced modest proliferation of cells when grown on fibronectin with dihydrotestosterone the most mitogenic of the three steroids. These data
are consistent with sex steroids playing a role in melanoma progression.
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oestrogen receptors (oestrogen receptor-a) nor did the majority of
melanoma tumours which we investigated (Dewhurst et al, 1997,
and Miller et al, 1997, respectively).
In the current study we have continued investigations of sex
steroid status and tumour progression for a cohort of patients with
advanced metastatic disease versus appropriately aged and sex-
matched controls and we have investigated to what extent the anti-
invasive effect of 17b-oestradiol is specific to oestrogenic steroids.
We report a modest reduction in sex hormone binding globulin
and oestrone with disease progression in male but not female
patients. Examining a range of steroids for anti-invasive activity,
we found oestrogenic compounds (17b-oestradiol and oestrone)
to inhibit invasion; steroids lacking the benzene ring structure did
not inhibit invasion, indeed dehydroepiandrosterone (DHEA),
which acts as a precursor to androgenic steroids, significantly
enhanced invasion of A375-SM cells through fibronectin by 40%.
Dihydrotestosterone also significantly stimulated proliferation of
these cells when grown on fibronectin but not when grown on
tissue culture plastic.
MATERIALS AND METHODS
Fibronectin (from human plasma), trypsin–EDTA, newborn calf
serum, basal medium eagle (BME-phenol free), insulin, trans-
ferrin, 17b-oestradiol (water soluble), oestrone, cortisol, sodium
bicarbonate, DHEA, progesterone, androstenedione, testosterone
and MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) were obtained from Sigma Chemical Company (Poole,
Dorset, UK). Penicillin–streptomycin, L-glutamine, vitamin
concentrate, non-essential amino acids, amphoteracin B (fungi-
zone), sodium pyruvate, Dulbecco’s modified Eagle’s medium
(DMEM) (with phenol red indicator), RPMI-1640 (both with and
without phenol red indicator), DMEM: nutrient mixture F-12 Ham
(1:1 mixture), nutrient mixture F-10 Ham were obtained from
Gibco BRL (Paisley, UK). Essential Modified Eaglés Medium
(EMEM) (10 ´ concentrate) was obtained from ICN
Pharmaceuticals (Oxfordshire, UK). Fetal calf serum (FCS) was
obtained from APP (West Midlands, UK). Transwell inserts were
obtained from Costar UK (High Wycombe, Buckinghamshire,
UK).
Cell lines and culture conditions
The human cutaneous melanoma cell line A375-SM was a
generous gift from IJ Fidler (USA) via MJ Humphries (University
of Manchester, UK). These cells were maintained by serial
passages in EMEM supplemented with pencillin (100 U ml–1),
streptomycin (100 mg ml–1), Fungizone (1.2 mg ml–1), L-glutamine
(2 mM), sodium pyruvate (1 mM), vitamin concentrate (1.5% of
100 ´ stock), non-essential amino acids (1%), sodium bicarbonate
(0.187%) and FCS (10%) at 37°C in a 5% carbon dioxide 95% air
atmosphere. Their doubling time was 20 h.
The human cutaneous melanoma cell line HBL was a generous
gift of Professor G Ghanem (Laboratory of Oncology & Experi-
mental Surgery, Université Libre de Bruxelles, B-1000 Brussels).
These cells were maintained by serial passage in nutrient mixture
F-10 Ham supplemented with penicillin (100 U ml–1), strepto-
mycin (100 mg ml–1), L-glutamine (2 mM), FCS (5%) and newborn
calf serum (5%). Their doubling time was around 24 h.
Invasion assay
The invasion assay used was as recently described from this lab-
oratory (Dewhurst et al, 1997). Transwell inserts, containing a
polycarbonate filter with 8-mm-diameter pores randomly dis-
tributed over its surface, were inverted and 50 ml of human
fibronectin (at 100 mg ml–1) added to underside of the polycar-
bonate filter and left for 1 h at 37°C in a 5% carbon dioxide 95%
air atmosphere. The inserts were then placed the correct way up in
wells of a 24-well plate containing 600 ml of the serum-free
medium. All cell types used in the study were removed from
the tissue culture flasks using 0.5 g l–1 trypsin–0.2 g l–1 EDTA,
centrifuged at 250 g for 5 min and then resuspended in serum-free
medium.
Cell suspensions (50 ml containing approximately 1.2 ´ 105
cells) plus an equivalent volume of serum-free medium (with or
without drug) were then added to each transwell. (In studies exam-
ining the effect of different media on cell invasion, cells were
cultured in the medium in question for 2 days prior to investigation
of the effects of this medium (minus FCS) on steroid inhibition of
invasion). Cells were then left for 20 h at 37°C in a 5% carbon
dioxide 95% air atmosphere. The time of 20 h was chosen as, by
this time, sufficient invasion had occurred, and it was below the
doubling time of the cells used. Following examination under the
light microscope, all cells in the experiment were counted using
the following techniques. The medium containing cells was
collected from the upper and lower chambers and replaced with an
equivalent volume of trypsin–EDTA to remove the remaining cells
from the assay. Cell number (of trypsinized cells plus any in the
media in the upper and lower chambers) was then determined
using a haemocytometer. Invaded cells were counted as those
removed from the underside of the filter, suspended in the medium
of the 24-well plate or attached to the bottom of the well. Non-
invaded cells were counted as those remaining in the transwell or
attached to the upper surface of the filter. The percentage of the
total amount of cells that had invaded through fibronectin over
20 h was then calculated.
Cell proliferation
The MTT-eluted stain assay (MTT-ESTA) was used to examine
changes in cell number as previously described from this labora-
tory (Mac Neil et al, 1993). This colourimetric assay is based on
assessing cellular dehydrogenase activity which indirectly reflects
cell number. In these experiments, cells were plated on either
tissue culture plastic or fibronectin in the presence and absence of
10% FCS.
Dilution of steroids
Dilutions of aliquoted steroids were made up as 10 mM stocks in
ethanol and stored at 4°C until required for use. Steroids were then
diluted in serum-free media as required. All steroids were exam-
ined at concentrations which spanned their physiological range
and did not exceed it by more than 1 log order.
Selection of patients and control subjects
Patients who were approached to join the study were those
attending the Weston Park Hospital Out-Patients Clinic. All volun-
teer patients gave written consent for the study under a protocol
2026 B Richardson et al
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approved by the Ethical Committee of the Northern General
Hospital Trust and Weston Park Hospital Sheffield. None of these
patients were receiving any treatment at the time of the study.
Twenty millilitres of blood was taken, separated into serum and
aliquots of serum stored at –80°C until analysis.
Control subjects were age matched and obtained by using
excess serum received from subjects who had undergone venesec-
tion for routine preoperative assessment screening (five male, four
female), cholesterol screening (nine male, six female), pre-cardiac
angiography (three male, three female) and non-specific tiredness
(two male, two female). Female subjects were also matched for
menopausal status using the ratio of FSH/LH. In controls this was
0.35 (95% confidence limits were 0.31–0.4) compared with 0.37
for melanoma patients (95% confidence limits of 0.31–0.43).
Measurement of sex steroids and sex hormone binding
globulin (SHBG)
Leuteinizing hormone (LH), follicle stimulating hormone (FSH),
testosterone and oestradiol were measured using chemilumines-
cent immunoassays from Chiron Diagnostics (Halsted, Essex, UK)
on an ACS:180 analyser. The coefficients of imprecision ranged
from 5 to 7% for LH, 5–7% for FSH, 6–20% for testosterone and
5–25% for oestradiol. The testosterone assay was selected because
it gives good agreement with a reference method (Wheeler et al,
1996; Wians et al, 1997). The oestradiol method was selected on
its negligible cross-reactivity with a wide range of natural and
synthetic oestrogens. Low concentrations of oestradiol and testos-
terone were confirmed by repeat analysis.
Oestrone (CV 7–12.5%) was measured using a radio-
immunoassay from IDS Ltd. (Bolden, Tyne & Wear, UK). SHBG
(CV, 4–8%) was measured by IRMA (Pharmacia & Upjohn,
Milton Keynes, UK).
Statistical analysis
Comparison of levels of steroids, FSH, LH and SHBG between
melanoma patients and controls were undertaken by Wilcox rank
non-parametric analysis. Students’ paired and non-paired t-tests
were used as appropriate for analysis of in vitro data.
Table 1 Age and sex distribution of melanoma patients and of controls
Group Male Female
No. Median No. Median Total
(range) (range)
Controls 19 53 (17–70) 15 60 (47–79) 34
Melanoma stage 1 & 2 3 28 (18–51) 0 – 3
Melanoma stage 3 9 51 (35–74) 6 60 (50–74) 15
Melanoma stage 4 5 47 (37–57) 9 64 (41–81) 14
Total 36 30 66
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Figure 1 Comparison of the accumulative age distribution for patients with stage 3 (A) and stage 4 (B) melanoma attending Weston Park Hospital, Sheffield
1998. Accumulative data for male patients is depicted by (n n) and for female patients by (•)2028 B Richardson et al
British Journal of Cancer (1999) 80(12), 2025–2033 © 1999 Cancer Research Campaign
RESULTS
Retrospective analysis of age and sex distribution for
Sheffield melanoma patients
The database of patients with melanoma presenting for treatment
in Sheffield Weston Park Hospital was examined initially for the
age and sex distribution of patients presenting with melanoma
stage 1–4. Of 196 patients on this database, the age distribution for
accumulative presentation did not differ for male and female
patients presenting with stage 1 and 2 melanoma. However, there
were comparatively few patients with stage 1 and 2 melanoma
(12 male and eight female attending this clinic). However, for the
69 patients with stage 3 melanoma, 40% of all male patients with
stage 3 tumours were aged 50 or less compared to only 20% of all
female patients with stage 3 (Figure 1A). For the 56 male and
61 female patients with stage 4 melanoma there was no difference
in accumulative age distribution (Figure 1B).
Prospective study of relationship between sex steroid
status and disease progression
Thirty-two volunteers and 34 appropriately age- and sex-matched
controls (obtained as described in Materials and Methods) were
recruited into a study in which they donated blood for analysis of
soluble S-100 and sex steroids and SHBG. For patients, informa-
tion related to age, menopausal status, medication which might
influence sex steroid and receptor levels (e.g. contraceptive pill or
hormone replacement therapy) and height and weight (to calculate
the body mass index) were also recorded. Table 1 summarizes the
age and sex distribution of melanoma patients and controls.
Figure 2 illustrates the data obtained for sex steroids and SHBG
versus melanoma stage for male and female patients respectively.
From this it can be seen that SHBG levels were lower in men with
stage 4 tumours (although this failed to achieve statistical signifi-
cance,  P < 0.07) and that oestrone levels were significantly
reduced in men with stage 2 tumours (P < 0.05) and also lower for
all male subjects compared to control male subjects (P < 0.03)
(not depicted in Figure 2).
Table 2 summarizes the data obtained for male and female
patients and controls. For the majority of comparisons, we found
melanoma patients differed from age- and sex-matched controls in
relatively few respects – as stated oestrone was lower for all male
patients compared to male controls and for stage 2 male melanoma
patients as a group; SHBG in male stage 4 patients was approxi-
mately half the value seen in male controls but failed to achieve
statistical significance on Wilcox analysis. The table also shows
free androgen index (FAI) (obtained by dividing testosterone by
SHBG concentration) and the ratio of oestrogens to androgens
(E/A). There were no significant changes in either with disease
progression.
In vitro study of influence of sex steroids on melanoma
cell invasion
We initially extended previous studies looking at the influence of
tissue culture media on tumour cell invasion. A comparison of six
media (as detailed in Table 3) showed that the anti-invasive
response to 17b-oestradiol was seen most clearly in RPMI-1640
medium. In the presence of F12:DMEM we failed to see any anti-
invasive response to 17b-oestradiol when examined at concentra-
tions up to 1 mM. Responses to 17b-oestradiol in the other media
were intermediate between the two. Subsequently, all studies were
undertaken using medium RPMI-1640 (phenol-free).
We compared seven structurally related steroids for their ability
to influence invasion. Figure 3 illustrates combined data from a
minimum of 3–8 experiments with each steroid and Table 4
summarizes the reference ranges for physiological concentrations
of sex steroids and summarizes the overall extent of steroid
influence on invasion of A375-SM in vitro.
From Figure 3 and Table 4 it is clear that (as previously
reported) 17b-oestradiol inhibits invasion in these cells. However,
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Figure 2 Comparison of levels of sex steroids and of SHBG in male and
female melanoma patients versus disease stage in comparison with aged
and sex matched controls. Histograms show means ± s.e.m. of data depicted
in Table 2. Values differing significantly from controls are indicated by
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oestrone was approximately 50 times more potent than 17b-
oestradiol in this respect. The other steroids tested, testosterone,
androstenedione, progesterone and cortisol did not significantly
affect invasion, although results with all of these steroids were
slightly above the control level of invasion seen in the absence of
steroid. Only in the case of DHEA did the increase in invasion
achieve statistical significance as shown in Figure 3 and noted in
Table 4.
Confirmation of the anti-invasive effects of oestradiol and
oestrone in another cell line was obtained using the HBL human
melanoma cell line. Figure 4 illustrates the ability of oestradiol and
oestrone to inhibit invasion of this cell line although the potency of
both steroids in this cell line was approximately 100-fold less than
in the A375-SM cell line.
In vitro study of influence of sex steroids on melanoma
cell proliferation
Figure 5 illustrates the combined data of 6–10 experiments in
which A375-SM cells were grown on either tissue culture plastic
or fibronectin in the presence of a range of concentrations of di-
hydrotestosterone, 17b-oestradiol and oestrone. Initial experiments
were conducted over 24 and 48 h and in the presence and absence
of FCS. Analysis of the data revealed that similar results were
obtained irrespective of whether incubation length was 24 or 48 h
and whether FCS was present or absent. Accordingly, all results
were combined and are shown in Figure 5.
Steroids did not affect proliferation of cells grown on tissue
culture plastic (with the exception of higher concentrations of
dihydrotestosterone which significantly reduced proliferation of
cells) (Figure 5C). Also, fibronectin was not itself mitogenic for
these cells (results not shown). However, we found that when cells
were grown on fibronectin, there was a modest mitogenic effect of
all three steroids. This achieved statistical significance in the case
of oestrone, although the stimulation of proliferation was only of
the order of 5–10%, did not achieve significance in the case of
oestradiol (as variation between experiments was large) but clearly
was most marked in response to dihydrotestosterone where the
average increase in proliferation was of the order of 40% (P < 0.05
at concentrations of 10–9 to 10–6 M). (In one particular experiment,
dihydrotestosterone induced a 70% increase in proliferation within
24 h.)
DISCUSSION
The purpose of this study was to obtain more basic information on
the extent to which cutaneous melanoma cells might be steroid-
sensitive, focusing in particular on whether steroids influence
interaction of melanoma cells with extracellular matrix (ECM)
proteins.
For the majority of patients with metastatic melanoma, prog-
nosis depends on the depth of extension of malignant melanocytes
into the dermis. Clinically, once the melanoma tumour is con-
sidered to have begun to metastasize, patients may be offered
chemotherapeutic or immunomodulatory therapy to retard
metastatic spread or increase the disease-free interval. However,
at present, patients presenting with thin tumours are not usually
offered any prophylactic treatment following surgical excision. If
Table 2 Statistical analysis of relationships between sex steroid status and melanoma stage
Melanoma stage
Factor Sex Control 1 & 2 3 4
Oestradiol M 53 ± 10 42 ± 19 67 ± 16 81 ± 27
(pmol l)–1 F1 1   ± 3 – 42 ± 28 32 ± 15
Oestrone M 186 ± 17 106 ± 15a,b 146 ± 24a 145 ± 30a
(pmol l–1) F 133 ± 9 – 117 ± 16 116 ± 8
Total estrogens M 239 ± 26 148 ± 55 214 ± 38 227 ± 40
(pmol l–1) F 145 ± 10 – 159 ± 30 148 ± 19
Testosterone M 15 ± 2 16 ± 7 12 ± 2 12 ± 2
(nmol l–1) F 0.6 ± 0.5 – 1.0 ± 0.4 1.6 ± 0.8
SHBG M 39 ± 5 38 ± 20 34 ± 5 23 ± 4
(nmol l–1) F 59 ± 8 – 48 ± 9 63 ± 8
FAI M 46 ± 7 48 ± 6 42 ± 8 53 ± 10
F 1.5 ± 0.4 – 2.0 ± 0.5 3.2 ± 2.5
E/A M 19 ± 2.6 13 ± 5 22 ± 6 26 ± 9
F 479 ± 117 – 602 ± 247 275 ± 101
LH M 3.9 ± 0.3 3.2 ± 1.0 4.3 ± 0.8 3.0 ± 0.4
(IU l–1) F 26 ± 3 – 41 ± 9 28 ± 7
FSH M 6 ± 15   ± 17   ± 27   ± 2
(IU l–1) F 75 ± 7 – 110 ± 21 73 ± 14
aOestrone values for all male patients are significantly lower (P < 0.05) than for control values. bP < 0.05 by
Wilcoxon analysis compared to control values.
Table 3 Effect of media on ability of 17b oestradiol to inhibit invasion of
A375-SM melanoma cells
Media % Control invasion seen with 1 mM 17b oestradiol
c±s.e.m n Significance
F12:DMEM 100 ± 56 3 NS
BME 61 ± 12 3 P < 0.05
F12-HAM 48 ± 53P < 0.05
DMEM 40 ± 19 3 P < 0.05
EMEM 37 ± 77P < 0.001
RPMI-1640 27 ± 10 5 P < 0.0012030 B Richardson et al
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Figure 3 The effects of steroids on invasion of A375-SM cells through fibronectin. Results show the means ± s.e.m. of 3–8 experiments. Values have been
expressed as a percentage of the invasion seen in the absence of any additions. Values differing significantly from invasion in the absence of steroids are
indicated by *P < 0.05, **P < 0.01 and ***P < 0.001 as determined by Student’s paired t-test. The Figure also depicts the structure of these steroids
Table 4 Physiological ranges of steroids
Steroid Physiological concentration range Overall effect on invasion of A375-SM
cells in vitro
Cortisol Male 138–635 nM No significant effect up to 1 nM
Female a 138–635
b 138–635
Progesterone Male 0.4–3.1 pM No significant effect up to 100 nM
Female a 0.5–79.5
b 0.5–2.2
DHEA Male 0.3–16.7* nM Significant stimulation at 1 nM
Female a 0.8–21.1 (143 ± 12, P < 0.05)
b 0.8–7.0
Androstenedione Male 2.6–7.2 nM No significant effect up to 100 nM
Female a 3.0–9.6
b 3.0–9.6
Testosterone Male 0.5–38.2 nM No significant effect up to 100 nM
Female a 0.5–2.4
b 0.5–2.4
17b oestradiol Male 37–184 pM Significant inhibition from 1 nM
Female a 73–2753
b <73
Oestrone Male 55–240 pM Significant inhibition from 10 pM
Female a 55–925
b 55–204
a, Range for pre-menopausal women. b, Range for post-menopausal women. * Male levels also fall with age, e.g. > 50 (0.3–11.1)Sex steroids and melanoma progression 2031
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sex steroids can affect the likelihood of tumours metastasizing
then this is worth investigating further because of the potential it
offers with respect to prevention of initial metastasis.
For these reasons we have looked in some detail at a number of
aspects of patients circulating sex steroid status and tumour
progression and the direct effects of sex steroids on melanoma
proliferation and invasion in vitro.
The patients attending Weston Park Hospital for treatment for
metastatic melanoma did not differ with respect to age and sex
when presenting with thin early stage tumours (stage 1 and 2).
However, there were relatively few patients with early stage
melanoma attending this clinic. There was a noticeable age differ-
ence in the male and female patients for stage 3 melanoma. Using
age 50 as an approximate indicator of menopause, twice as many
men had presented with stage 3 by age 50 compared to women by
age 50. However, when one looked at the age distribution of
patients with stage 4 melanoma, no sex difference was seen.
We suggest that one interpretation of this data is that any female
advantage in melanoma cannot be seen if one looks at patients
presenting with early stage (thin melanoma or adjacent metas-
tasis). However, there is an interesting discrepancy in the stage 3
melanoma sex distribution. Melanomas may progress to stage 3
more slowly in female than male patients. Subsequent progression
from stage 3 to stage 4 melanoma does not show any evidence of a
female survival advantage. We recognize this is a relatively crude
analysis of this database, but suggest that it does reflect the clinical
epidemiology seen in many other larger databases which show
progression in premenopausal females is slower than in males or
post-menopausal women (Cocconi et al, 1992). Thus, oestrogens
could be responsible, at least in part, for the delayed progression to
stage 3 disease in the women. However, this suggestion requires
analysis using a much larger database of patients with ideally a
progressive study of menopausal status and disease progression.
We recognise that many factors influence melanoma progression
and that the disease does not necessarily progress through each
stage in every patient also.
For the cohort of patients for whom we investigated their circu-
lating sex steroid and sex hormone binding globulin status, we
found relatively few differences overall. Two differences that we
did find and were unable to explain in terms of patient age or body
mass index were a decrease in SHBG in male patients with
advanced melanoma (which just failed to achieve statistical signif-
icance, P < 0.07) and a significant decrease in circulating levels of
oestrone in male patients. The reduced SHBG in male patients
with melanoma confirmed this finding in our previous study
(Miller et al, 1997). The reduced levels of SHBG in male patients
with stage 4 disease did not relate to any decrease in body mass
index which we excluded for these patients (results not shown).
There is currently no known role of SHBG in melanoma.
Perhaps the most important property of SHBG is that it regulates
the levels of free androgens and oestrogens in the serum, thereby
controlling diffusion of the free fraction of steroids from plasma
into the tissues. It binds 5a-dihydrotestosterone and testosterone
with high affinity and oestradiol with lower affinity (Petra, 1991).
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Figure 4 Comparison of the ability of 17b-oestradiol (•) and oestrone (n n)
to inhibit invasion of the HBL melanoma cell line. Results show the mean ±
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significantly from invasion in the absence of drugs are indicated by *P < 0.05
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Figure 5 Effect of steroids on proliferation of A375-SM cells cultured on
tissue culture plastic (•) or on fibronectin (l l). Results shown are for (A)
oestradiol, (B) oestrone and (C) dihydrotestosterone. Values shown are
means ± s.e.m. expressed as a percentage of the proliferation in the
absence of steroid. Results shown are means of 6–10 experiments. Values
differing significantly from proliferation in the absence of steroid are indicated
by *P < 0.05, **P < 0.01 and ***P < 0.001 by Student’s paired t-test2032 B Richardson et al
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The production of SHBG by the liver is influenced by several
factors. Androgens decrease the production of SHBG by the liver,
but oestrogens, thyroid hormones and insulin all increase the
production of SHBG. Increasing amounts of oestrogen can have a
devastating effect on the bio-availability of androgens. As
oestrogen concentration increases so does the SHBG level.
Increasing amounts of SHBG bind testosterone thus decreasing
bio-available testosterone. In vitro studies have shown that the
addition of pure SHBG to endometrial cancer cells maintained in
culture appear to inhibit the incorporation of 17b-oestradiol into
cancer cells (De Ryck et al, 1985). This supports the premis that
the unbound steroid fraction enters into cells and represents the
active form of the hormone. A decrease in SHBG in stage 4
melanoma for male patients might suggest that melanoma cells
would be exposed to greater levels of male sex hormones in this
late-stage disease. Interestingly, large increases in SHBG have
been reported as a long-term effect of tamoxifen therapy for breast
cancer (Jordan et al, 1987; Cuzick et al, 1993). Also a direct role of
SHBG in transporting sex steroids across the plasma membrane
cannot be ruled out. Rosner et al (1991) have demonstrated that
SHBG has its own receptor sites on plasma membranes. If the
SHBG binding site is occupied by a steroid then it cannot bind to
its receptor. However, if unliganded SHBG is allowed to bind to its
receptor on intact cells and an appropriate biologically active
steroid hormone is then introduced the second messenger cyclic
AMP is increased. Thus Rosner et al have demonstrated an addi-
tional mode of action of steroid hormone, one that does not require
that the steroid interacts with the steroid receptor.
Differences between the sexes in the patient and volunteer
groups that were unrelated to disease progression were obviously
due to the very high free androgen index in all male volunteers in
the study compared to female volunteers. The oestrogen/androgen
index was decreased in stage 4 females, but the variation was such
that this did not achieve statistical significance. However, the
current study leaves open the possibility that oestrogens may
retard melanoma progression and that conversely androgens may
actively stimulate aspects of tumour growth. (We also, in this
study, measured soluble S-100 to use this hopefully as an indicator
of disease stage. However, we were unable to confirm its useful-
ness in this respect in this study, as all but four controls and four
patients showed levels of S-100 beneath the limits of detection. On
investigation, control subjects were not found to be suffering from
conditions likely to elevate S-100, results not shown.)
Turning next to the question of whether melanoma tumours
themselves contain oestrogen receptors, we have previously failed
to find convincing evidence of oestrogen receptor-a in a large
number of melanoma tumours or in the A375-SM cell line used in
this study (Dewhurst et al, 1997; Miller et al, 1997). However, the
recent cloning of oestrogen receptor-b offers an explanation to the
conflicting data in the literature concerning binding of radiola-
belled oestradiol in the absence of any specific oestrogen receptor-
a receptors (Duncan et al, 1994; and as discussed in Miller and
Mac Neil, 1997).
At present, the function of ERb is under intense investigation.
Early reports suggest that acting at the level of transcription
factors, it affects gene transcription with quite a different profile of
gene regulation to oestrogen receptor-a. Skin has previously been
reported to be positive for ERb although at low levels
(Brandenberger et al, 1997). It does not appear that melanoma has
yet been investigated for the ERb mRNA or the ERb protein. In
view of the absence of oestrogen receptor-a in the A375-SM cell
line and its responsiveness to oestrogens (as shown in this study in
terms of both invasion and proliferation) and the epidemiological
evidence showing female survival benefit in melanoma despite the
lack of oestrogen receptor-a in the majority of tumours, this is
obviously an area which merits investigation.
In looking at the effects of steroids on invasion of cutaneous
melanoma cells in vitro, we have, as in our first report on this area
(Dewhurst et al, 1997), used a relatively simple model of
melanoma cells invading through fibronectin. Fibronectin is
normally absent or at very low concentrations in normal skin but
will be produced rapidly by dermal fibroblasts as part of a transi-
tional matrix in wound healing. Melanoma cells have been found
to secrete soluble factors which are capable of influencing the
glycosaminoglycan component of the extracellular matrix
produced by fibroblasts (Edwards et al, 1992). There are also
a number of immunohistochemical reports consistent with
melanoma cells inducing considerable turnover and breakdown
of matrix associated with invasion.
We undertook experiments looking at the possible mitogenic
effect of steroids on A375-SM cells both on tissue culture plastic
and on fibronectin primarily to examine whether any mitogenic
effects of the steroids were likely to occur in the invasion assay
(albeit this is only 20-h duration). We were surprised to discover
that the steroids we examined did not affect melanoma prolifera-
tion when cells were grown on tissue culture plastic but did
when cells were grown on fibronectin. Fibronectin itself was not
mitogenic for these cells hence our data gives clear evidence
of a synergism of the effects of fibronectin and of steroids
(dihydrotestosterone, in particular) in inducing proliferation of
melanoma cells. Steroids influence wound healing, e.g. wound
healing in pregnancy is often exaggerated and hypertrophic scars
and hyperpigmentation are relatively common. While the extent of
the mitogenic response to the steroids is modest under the circum-
stances so far investigated in vitro, we now need to conduct further
work to explore longer periods of exposure to the steroids in the
presence of a range of matrix proteins.
When we looked at the effect of seven different steroids on
A375-SM melanoma cell invasion, the results were very clear as
only the two oestrogenic compounds significantly reduced
invasion. It was also obvious that there was a slight (although
extremely variable) enhancement of invasion with some of the
androgenic compounds. This only achieved statistical signifi-
cance for DHEA due to the considerable variation seen in these
assays. The finding that DHEA positively affected invasion is
interesting from the structural viewpoint. Unlike the other andro-
gens tested, it has a double bond between the 5 and 6 carbon
atoms as opposed to the 4 and 5 carbon atoms in the other andro-
gens. We, therefore, have a situation where the structure of the A
ring of the steroids appears to influence the invasion of melanoma
cells. An A ring fully aromatized as in the oestrogens seems to
inhibit invasion. A complete lack of double bonds in the A ring as
in DHEA seems to enhance invasion. Although we would suggest
that these results based on one simple in vitro assay be interpreted
with caution at this stage, these data combined with the mitogenic
effect of dihydrotestosterone with fibronectin on melanoma cells
lead us to suggest that this work be extended into other models
of invasion both in vitro and in vivo. Certainly, the current work
is consistent with oestrogenic compounds being anti-invasive
and androgenic compounds clearly not sharing this property.
Progesterone did not reduce invasion of melanoma cells in these
experiments.Sex steroids and melanoma progression 2033
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While this study has been extremely useful in identifying which
steroids can affect melanoma cell invasion, the levels of these
steroids and SHBG now need to be studied in combinations which
reflect the circulating steroid status of the premenopausal versus
the post-menopausal woman, the pregnant female and the young
versus the old male.
We have not, in this study, looked into the mechanism of how
oestradiol or oestrone affects melanoma cell invasion through
fibronectin and this also remains to be investigated. However,
irrespective of the details of the mechanism, the implications of the
current study are that further work in this area might lead to the
development of a prophylactic approach to preventing melanoma
cells interacting effectively with ECM proteins and invading from
the site of the initial tumour.
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